Clinical Edge Journal Scan

Hepatis D virus linked to liver cancer in patients with chronic HBV


 

Key clinical point: Consider testing for hepatitis D virus in patients receiving nucleoside/nucleotide analogues (NA) for chronic hepatitis B virus infection (HBV).

Major finding: Prevalences of anti-HDV and HDV RNA positivity were 2.3% and 1.0%, respectively. Five-year cumulative rates of hepatocellular carcinoma (HCC) were 22.2% among patients with detectable HDV RNA vs 7.3% among patients with undetectable HDV RNA ( P = .01).

Study details: This was a single-center retrospective study of 1,349 patients receiving NA for chronic HBV.

Disclosures: The Center for Liquid Biopsy, Center for Cancer Research, Cohort Research Center, Kaohsiung Medical University, and Kaohsiung Medical University Hospital provided funding. Two coinvestigators disclosed ties to Abbott, BMS, Gilead, Merck, AbbVie, Roche, and IPSEN. The other investigators reported having no conflicts of interest.

Source: Jang T-Y et al. Sci Rep. 2021 Apr 14. doi: 10.1038/s41598-021-87679-w

Recommended Reading

Clinical Edge Journal Scan Commentary: HCC May 2021
Federal Practitioner
High PIGC expression predicts poor liver cancer survival
Federal Practitioner
High serum Angiopoietin 2 identified patients with HCC
Federal Practitioner
Transplant rejection linked to recurrence of HCC
Federal Practitioner
Study eyes lenvatinib combination in unresectable liver cancer
Federal Practitioner
GINS4 oncogene linked to higher-grade liver cancer, worse survival
Federal Practitioner